Skip Navigation
Skip to contents

Endocrinol Metab : Endocrinology and Metabolism

clarivate
OPEN ACCESS
SEARCH
Search

Author index

Page Path
HOME > BROWSE ARTICLES > Author index
Search
Stephen C. Bain 1 Article
Diabetes, Obesity and Metabolism
Glucagon-Like Peptide 1 Therapy: From Discovery to Type 2 Diabetes and Beyond
Adie Viljoen, Stephen C. Bain
Endocrinol Metab. 2023;38(1):25-33.   Published online February 6, 2023
DOI: https://doi.org/10.3803/EnM.2022.1642
  • 2,375 View
  • 286 Download
  • 3 Web of Science
  • 4 Crossref
AbstractAbstract PDFPubReader   ePub   
The therapeutic benefits of the incretin hormone, glucagon-like peptide 1 (GLP1), for people with type 2 diabetes and/or obesity, are now firmly established. The evidence-base arising from head-to-head comparative effectiveness studies in people with type 2 diabetes, as well as the recommendations by professional guidelines suggest that GLP1 receptor agonists should replace more traditional treatment options such as sulfonylureas and dipeptidyl-peptidase 4 (DPP4) inhibitors. Furthermore, their benefits in reducing cardiovascular events in people with type 2 diabetes beyond improvements in glycaemic control has led to numerous clinical trials seeking to translate this benefit beyond type 2 diabetes. Following early trial results their therapeutic benefit is currently being tested in other conditions including fatty liver disease, kidney disease, and Alzheimer’s disease.

Citations

Citations to this article as recorded by  
  • The Road towards Triple Agonists: Glucagon-Like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide and Glucagon Receptor - An Update
    Agnieszka Jakubowska, Carel W. le Roux, Adie Viljoen
    Endocrinology and Metabolism.2024; 39(1): 12.     CrossRef
  • Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action
    John R. Ussher, Daniel J. Drucker
    Nature Reviews Cardiology.2023; 20(7): 463.     CrossRef
  • A new class of glucose-lowering therapy for type 2 diabetes: the latest development in the incretin arena
    Stephen C Bain, Thinzar Min
    The Lancet.2023; 402(10401): 504.     CrossRef
  • Flattening the biological age curve by improving metabolic health: to taurine or not to taurine, that’ s the question
    Kwok M. Ho, Anna Lee, William Wu, Matthew T.V. Chan, Lowell Ling, Jeffrey Lipman, Jason Roberts, Edward Litton, Gavin M. Joynt, Martin Wong
    Journal of Geriatric Cardiology.2023; 20(11): 813.     CrossRef
Close layer

Endocrinol Metab : Endocrinology and Metabolism